文献速递临床试验与 GCP基础与转化研究

移植前阿奇霉素给药对肾移植功能影响的双盲随机试验方案

Effects of pre-transplant azithromycin administration on kidney graft function: study protocol for a double-blind randomized clinical trial.
PubMed 文献 · Trials · 2018-06-28

该研究为单中心双盲随机临床试验,计划将60例肾捐献者随机分配至阿奇霉素组或安慰剂组,术前1天单次口服1g阿奇霉素或安慰剂。主要结局为移植肾功能,次要结局包括排斥率、受者尿路感染、活体捐献者疼痛及全身炎症反应综合征、双方并发症,并评估不良反应。

要点

  • 肾捐献者术前1天单次1g阿奇霉素或安慰剂,评估移植肾功能。
  • 次要结局包括排斥率、受者尿路感染及捐献者/受者并发症。
  • 若有效,阿奇霉素可能成为降低移植后风险的简便经济干预。

核心结论

  • 理论上供者使用阿奇霉素可通过肾脏蓄积实现移植物免疫调节并改善移植结局,尚待本试验验证。

研究设计与样本

  • 单中心、双盲、随机临床试验,计划纳入60例肾捐献者,随机分为阿奇霉素组或安慰剂组。
  • 干预为术前1天单次口服阿奇霉素1g或安慰剂。
  • 招募于2016年9月开始,预计2018年3月完成。

关键数值与推荐

  • 主要结局为移植肾功能;次要结局包括排斥率、受者尿路感染、活体捐献者疼痛和全身炎症反应综合征、双方并发症。
  • 结局在基线、移植后第一周每日、移植后1个月和3个月评估。
  • 不良反应将被记录。

临床怎么用

  • 若试验证实阿奇霉素可减少不良结局,可作为简便经济的干预降低移植后风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney transplantation is the best strategy for the management of end-stage renal disease; however, the outcomes need to improve further. Macrolides show antimicrobial and anti-inflammatory properties in chronic diseases and intraoperatively, and can accumulate in tissues for extended periods. Therefore, theoretically, when administered to a donor and because of accumulation in the donor kidney, macrolides can cause graft immunomodulation and improve kidney transplantation outcomes. METHODS: This study is a single-center, randomized clinical trial. A total of 60 kidney donors will be randomly allocated to the azithromycin or placebo group and treated with a single dose (1 g) of azithromycin or placebo, respectively, 1 day before surgery. Recruitment commenced in September 2016 and is expected to be completed by March 2018. The primary outcome is kidney graft function. The secondary outcomes include rejection rate, urinary tract infections in graft recipients, pain and systemic inflammatory response syndrome in live donors, and complications in both donors and recipients. Outcomes will be evaluated at baseline and every day in the first week after transplantation, as well as at 1 and 3 months post transplantation. Adverse reactions will be documented. If the efficacy of azithromycin in reducing adverse outcomes is confirmed, it would serve as an easy to use, economic intervention able to lower post-transplantation risks. DISCUSSION: Short and mid-term analyses of blood and urine samples as well as immunological assays will facilitate a more in-depth analysis of the effects of azithromycin on transplantation outcomes. TRIAL REGISTRATION: Iranian Clinical Trial Registry, IRCT201606141853N11 , registered on September 5, 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mokhtari G, Teimoori M. Effects of pre-transplant azithromycin administration on kidney graft function: study protocol for a double-blind randomized clinical trial. Trials. 2018. PMID: 29950182. doi:10.1186/s13063-018-2744-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。